Vasoactive neuropeptide

VIP (Vasoactive Intestinal Peptide)

The 1978 Domschke infusion study in four healthy volunteers measured a plasma disappearance half-time for VIP of one minute; the app lists 0.02 hours, about 1.2 minutes.1

Limited evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

VIP (Vasoactive Intestinal Peptide) after one dose: 50% at ~0.02 h, 25% at 0.04 h, 12.5% at 0.06 h.

Drawn from the half-life in the app's model, ~0.02 h. The model's figures

Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide that acts at VPAC1 and VPAC2 receptors, according to the app's notes. The app files it as a vasoactive peptide and lists a nasal route, a typical dose of 50 to 200 mcg/day, and a bioavailability of 30%, which the app's notes call an estimate. The app grades the evidence as limited.

The human evidence cited here comes from four kinds of work: a 1978 intravenous infusion study in four healthy volunteers, an open phase II trial of nebulised VIP in 20 people with sarcoidosis, trials of intravenous or inhaled aviptadil in COVID-19, and registry entries for those trials.1,2,3,4 Aviptadil is the name used in the registry entries for a synthetic form of human VIP.4 A query of PubMed on 16 November 2026 for intranasal VIP returned 26 records, and among the 20 titles listed none reports a trial of intranasal VIP in people; the titles listed include rat studies and studies of nasal secretions. Two queries of PubMed for papers combining VIP with the author Shoemaker and chronic inflammatory response syndrome returned 0 records. The app's notes attribute the real-world intranasal schedule of 50 mcg four times daily to a protocol by Shoemaker for chronic inflammatory response syndrome (CIRS), and describe that evidence base as roughly three papers by Shoemaker, none indexed in PubMed. Those papers are not cited here, because they could not be retrieved as primary sources.

The app's notes describe VIP as vasodilatory, bronchodilatory and anti-inflammatory, and as a local paracrine mediator rather than a bloodborne hormone. Domschke and colleagues reached a related conclusion from infusion data in 1978: "The present data, however, do not support a role for VIP as a circulating hormone, at least under physiological conditions".1 In the sarcoidosis trial, Prasse and colleagues report that nebulised VIP "significantly reduced the production of tumor necrosis factor-alpha by cells isolated from bronchoalveolar lavage fluids of these patients".2 The same report states that "In vitro experiments demonstrated the capacity of VIP to convert naive CD4(+)CD25(-) T cells into CD4(+)CD25(+)FoxP3(+) regulatory T cells", which is a laboratory result and not a measurement in the patients.2 The sponsor's description in the NCT04311697 registry entry states that "VIP binds to VPAC1 receptors on the pulmonary Alveolar Type II (ATII) cell" and cites nonclinical studies in animal models, which is the sponsor's account and not a trial result.4

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~0.02 h
Bioavailability
30%
Typical dose
50–200 mcg/day
Route
Nasal
Time to peak
~0.05 h

The human pharmacokinetic data among the sources cited come from the 1978 intravenous infusion study, in which plasma VIP was measured by radioimmunoassay.1

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life0.02 h (about 1.2 minutes)Average disappearance half-time of one minute after stopping intravenous infusions, with first order kinetics, in four healthy volunteers1
Bioavailability30% (nasal)Intranasal bioavailability is not published according to the app's notes, which call the 30% value an estimate; none of the sources cited here reports one4
Clearance and volume of distributionVolume of distribution not listed in the appApparent metabolic clearance rate about 9 ml/kg/min and apparent volume of distribution approximately 14 ml/kg, after intravenous infusion1
Time to peakAbout 0.05 h (3 minutes)Not reported for the nasal route in the sources cited; during infusion plasma levels reached a plateau, with "mean plateau levels of circulating VIP" in the range seen in the Verner-Morrison syndrome at the higher doses1

The app's half-life of 0.02 hours is close to the one-minute figure of Domschke and colleagues, which comes from intravenous infusion in four volunteers and not from any nasal dose.1 The app lists a duration of 6 hours; none of the sources cited gives a duration of effect for VIP given by the nose.1

4

Human studies

Table 4.1Human studies5 rows
Study and yearDesignPeopleDose and lengthMain result
Domschke and colleagues, Gut 19781Graded intravenous infusions with plasma measurement; no comparator group described1Four healthy volunteers10.6, 1.3 and 3.3 pmol/kg/min, each over 30 minutes1Disappearance half-time of one minute; at the highest dose the pulse rate and the amplitude of blood pressure were increased and cutaneous flushing occurred1
Prasse and colleagues, American Journal of Respiratory and Critical Care Medicine 20102Open phase II study220 patients with histologically proved sarcoidosis and active disease2Nebulised VIP for 4 weeks; the dose is not given in the record read2Reduced tumor necrosis factor-alpha production by bronchoalveolar lavage cells, and increased numbers of bronchoalveolar lavage CD4(+)CD127(-)CD25(+) T cells; the authors call inhalation "safe, well-tolerated"2
Registry entry NCT04311697, intravenous aviptadil in COVID-19, results posted4Randomised, quadruple-masked phase 2/3; sponsor APR Applied Pharma Research s.a.4203 participants enrolled; critical COVID-19 with respiratory failure4Aviptadil in escalating doses of 50, 100 and 150 pmol/kg/hr over 12 hours plus standard of care, against saline plus standard of care4Primary outcome at day 28 was "Resolution of Respiratory Failure (Alive and Free of Respiratory Failure)"; the TESICO authors cite "an exploratory efficacy signal from a previous Phase 2/3 randomized trial" as part of their rationale4,3
Brown and colleagues, TESICO, Lancet Respiratory Medicine 20233Randomised, placebo-controlled, 28 US sites; stopped for futility3461 adults hospitalised with COVID-19 acute hypoxaemic respiratory failure in the aviptadil comparison (231 aviptadil, 230 placebo)3Intravenous aviptadil, 12-hour infusions on 3 days, targeting 600, 1200 and 1800 pmol/kg3Day 90 odds ratio for a better outcome category 1.11 (95% CI 0.80–1.55; p=0.54); day 90 mortality 38% against 36% (HR 1.04; 95% CI 0.77–1.41)3
Registry entry NCT04536350, inhaled aviptadil in COVID-196Randomised, double-masked phase 2; terminated; the registry names the investigator Prof. Dr. Jörg Leuppi, Cantonal Hospital, Baselland, as lead sponsor6Registry lists an actual enrolment of 836Aviptadil 67μg nebulised three times a day for ten days, or 0.9% NaCl solution inhaled three times a day for 10 days, each with standard care6No results are quoted here; the registry gives the reason for stopping as "Difficulties recruiting participants for the Aviptadil study as there are nowadays very few hospitalized COVID patients"6

Deeper analysis: Domschke and colleagues, intravenous VIP in healthy volunteers

Domschke and colleagues published the infusion study in Gut in 1978, with Bloom among the authors.1 Four healthy volunteers received graded intravenous doses of 0.6, 1.3 and 3.3 pmol/kg/min, each over 30 minutes.1 The authors report that "Even with the smallest dose of VIP, plasma concentrations rose markedly above normal values".1 After the infusions stopped, levels fell "by first order kinetics with an average disappearance half-time of one minute".1 During the highest dose, "plasma concentrations of glucose, free fatty acids, and calcium were slightly but significantly raised, the pulse rate and the amplitude of blood pressure were increased, and cutaneous flushing occurred".1 The sample is four people and the description of the design gives no comparator group.1 The PMC record carries the paper's summary and reference list, so the authors' own limitations beyond that summary and any funding statement are not quoted here.1

Deeper analysis: Prasse and colleagues, nebulised VIP in sarcoidosis

Prasse and colleagues, from the Department of Pneumology, University Hospital, Freiburg, Germany, published the trial in the American Journal of Respiratory and Critical Care Medicine in 2010.2 The study treated 20 patients with histologically proved sarcoidosis and active disease with nebulised VIP for 4 weeks, in what the authors call "an open clinical phase II study".2 The measurements were on cells from bronchoalveolar lavage fluid, with tumor necrosis factor-alpha production reduced and CD4(+)CD127(-)CD25(+) T cells increased, which "showed regulatory activities on conventional effector T cells".2 The authors conclude that "This study is the first to show the immunoregulatory effect of VIP in humans".2 The record lists the publication type as "Research Support, Non-U.S. Gov't" and names no company funder in the lines read.2 The record read is the PubMed summary only, so the dose, adverse event counts, any clinical outcome measures, and the authors' stated limitations are not quoted here.2 The design is open, which the authors state, and the outcomes quoted are immune cell measurements, not symptom or lung function results.2

Deeper analysis: TESICO, intravenous aviptadil in COVID-19 respiratory failure

Brown and colleagues reported the aviptadil comparison of the ACTIV-3b/TESICO master protocol in the Lancet Respiratory Medicine in 2023.3 Adults were eligible if they had "acute hypoxaemic respiratory failure due to confirmed SARS-CoV-2 infection" and were within 4 days of its onset.3 Four hundred seventy-one of the 640 planned participants were randomised, and 461 received any infusion of blinded aviptadil (231) or placebo (230).3 The primary outcome, assessed at day 90, was a six-category ordinal outcome from being at home and off oxygen for at least 77 days to death.3 The odds ratio for being in a better category was 1.11 (95% CI 0.80–1.55; p=0.54), estimated for the 450 participants with known status on day 90, and cumulative mortality through day 90 was 38% (n=86) with aviptadil and 36% (n=83) with placebo.3 A composite safety outcome of death, serious adverse events, organ failure, serious infection, or grade 3 or 4 adverse events through day 5 occurred in 63% (n=146) of the aviptadil group and 56% (n=129) of the placebo group (OR 1.40; 95% CI 0.94–2.08; p=0.10).3 Twenty-four (10%) aviptadil and 13 (6%) placebo participants had an infusion discontinued due to an adverse event, and 71 (31%) and 35 (15%) had an infusion pause.3 Subgroup results varied: the odds ratio was 2.71 (95% CI 1.37–5.33) among non-Black Hispanic participants, 0.78 (95% CI 0.34–1.83) among Black participants and 0.76 (95% CI 0.46–1.23) among non-Hispanic White participants, and the authors write that the possible favourable effect among Hispanic participants "must be interpreted with caution, due to the absence of an overall treatment effect as well as the large number of subgroups assessed".3 The authors conclude: "we found no evidence to suggest that aviptadil has a therapeutic role for patients with COVID-19 acute hypoxemic respiratory failure".3 Their stated limitations include "First, the trial has limited power for subgroup analyses" and that "most participants had not been vaccinated".3 They also write that 24% of assigned participants did not receive the full prescribed aviptadil dose across the three infusion days, and that it is possible the dose or duration "was not ideal".3 Funding came from "the U.S. Operation Warp Speed program, the National Institute of Allergy and Infectious Diseases (NIAID)" and others, and "Trial medication was donated by NRx Pharmaceuticals (aviptadil) and Gilead Sciences, Inc. (remdesivir)".3 Two authors report "study materials from NeuroRx, Inc. and Gilead through the National Heart, Lung, and Blood Institute (NHLBI) subcontract, during the conduct of the study".3 The NIAID registry entry for the aviptadil comparison lists NCT06729606 as completed, phase 3, with 471 participants.5

Deeper analysis: the earlier phase 2/3 intravenous aviptadil trial (NCT04311697)

The registry entry lists APR Applied Pharma Research s.a. as lead sponsor, 203 participants, quadruple masking, and a primary outcome at day 28 of "Resolution of Respiratory Failure (Alive and Free of Respiratory Failure)".4 The entry's brief summary states the dose as "escalating doses from 50 -150 pmol/kg/hr over 12 hours" given with maximal intensive care against placebo.4 The posted results list resolution of respiratory failure at day 28 in 72 of 131 participants on aviptadil and 33 of 65 on placebo, and deaths in 46 of 131 and 30 of 65; 5 aviptadil and 2 placebo participants were randomised but not treated.4 The entry also lists a published report of the trial by Youssef and colleagues in Critical Care Medicine in 2022.4 The Youssef paper was not retrieved, so its results and its authors' stated limitations are not described here; the registry text carries the sponsor's own description, which says aviptadil has "a demonstrated 20 year history of safety in phase 2 trials".4 The TESICO authors describe the earlier trial's result as "an exploratory efficacy signal", and TESICO itself did not reproduce a benefit.3

5

Doses reported in studies and on labels

No single-ingredient label for VIP or aviptadil was among the sources cited; the one label cited, for Invicorp, is an injection combining aviptadil with phentolamine, so the table lists doses used in studies and registry entries.7

Table 5.1Doses reported in studies and on labels5 rows
SourceRouteDosePeople and length
App's typical doseNasal50 to 200 mcg/dayNot tied to any trial cited here; the app's notes give 50 mcg four times daily as the real-world schedule
Domschke and colleagues 19781Intravenous infusion0.6, 1.3 and 3.3 pmol/kg/min1Four healthy volunteers, 30 minutes per dose1
Prasse and colleagues 20102NebulisedDose not given in the record read220 patients with sarcoidosis and active disease, 4 weeks2
NCT04311697 (registry)4Intravenous infusion50, 100 and 150 pmol/kg/hr over 12 hours4203 enrolled, critical COVID-19 with respiratory failure4
TESICO, Brown and colleagues 20233Intravenous infusionTargeting 600 pmol/kg on day 1, 1200 pmol/kg on day 2 and 1800 pmol/kg on day 33461 adults, three daily 12-hour infusions against matched saline placebo3
6

Side effects reported

In the 1978 infusion study, the highest dose raised glucose, free fatty acids and calcium "slightly but significantly", increased the pulse rate and the amplitude of blood pressure, and caused cutaneous flushing.1 In TESICO, "Diarrhea, facial flushing, tachycardia and hypotension occurred more frequently on aviptadil than placebo", and these events were more common on the second and third infusion days, when higher doses were targeted.3 The authors state that "Most adverse events during or within 2 hours of completing the infusion were grade 1 or 2".3 Infusions were discontinued for an adverse event in 24 (10%) aviptadil and 13 (6%) placebo participants, and paused in 71 (31%) and 35 (15%).3 The composite safety outcome through day 28 occurred in 78% (n=181) of the aviptadil group and 75% (n=172) of the placebo group, with HR 1.17 (95% CI 0.95–1.44).3 Prasse and colleagues describe inhaled VIP in 20 people with sarcoidosis as "safe, well-tolerated" in an open study; the record read gives no adverse event counts.2 No trial of VIP by the nasal route was identified in the searches described above, so no side effect rate for that route is reported here.2

7

Bloodwork and markers

The app lists blood pressure, hs-CRP, VEGF, TGF beta-1 and MSH as markers to monitor, as its own figure and not a finding of the sources cited. For blood pressure, TESICO reports that on the second and third infusion days "mean arterial pressure (MAP) was 5–7mmHg lower among aviptadil vs. placebo participants during each infusion", returning to parity by 2 hours after the infusion ended.3 The 1978 study in healthy volunteers reports that at the highest infusion dose "the pulse rate and the amplitude of blood pressure were increased"; it does not report mean arterial pressure.1 The 1978 study also measured glucose, free fatty acids and calcium, which rose slightly but significantly at the highest dose.1 In sarcoidosis, tumor necrosis factor-alpha production by bronchoalveolar lavage cells was the reported inflammatory measure.2 None of the sources cited here reports hs-CRP, VEGF, TGF beta-1 or MSH measured after VIP in people.3

Pharmafile reported on 5 November 2021 that "The FDA has declined to grant Emergency Use Authorisation for NRx Pharmaceuticals’ therapy, Zyesami® (aviptadil), in the treatment of critical COVID-19 patients", citing "insufficient data regarding the benefits of Zyesami versus the risks".8 Managed Healthcare Executive reported on 1 July 2022 that the FDA declined an emergency use authorisation for Zyesami in patients "who had received remdesivir and continued to progress", on an application submitted "using data from a post-hoc subgroup analysis".9 Both reports are trade news and not FDA documents, and the FDA letters themselves were not retrieved.9 The investigator-written description in the NCT04536350 registry entry states that "In Europe, Aviptadil is approved for human use" and that "In the US, VIP has been given FDA Orphan Drug Designation for the treatment of ARDS", without naming a product, indication or date for the European statement.6 In Sweden, the product information for Invicorp, an injection into the penis for erectile dysfunction in adult men, lists aviptadil (VIP) as one of its two active ingredients, with phentolamine.7 The status of VIP on the WADA Prohibited List and any approval of an intranasal VIP product were not established from the sources cited here.8

9

What is not known

  • None of the sources cited here measures the pharmacokinetics or bioavailability of intranasal VIP in people; the app's 30% is described in the app's notes as an estimate.
  • None of the sources cited here ties the app's range of 50 to 200 mcg/day to a trial; the doses stated in the studies above are intravenous and given in pmol/kg, and the nebulised sarcoidosis dose is not in the record read.
  • The sarcoidosis trial was open, enrolled 20 people, and reported immune cell measures, so whether nebulised VIP changes clinical outcomes is not answered by the record read.
  • Intravenous aviptadil did not improve day 90 outcomes or mortality against placebo in TESICO; whether other doses, routes or conditions differ is not answered by that trial.
  • The Shoemaker intranasal schedule rests on papers that were not retrieved, so its claimed effects are not described here.
What is the half-life of VIP?

Domschke and colleagues measured an average disappearance half-time of one minute after intravenous infusion in four healthy volunteers, and the app lists 0.02 hours.1

Is VIP a circulating hormone?

The 1978 infusion study concluded that its data "do not support a role for VIP as a circulating hormone, at least under physiological conditions".1

Did aviptadil work for COVID-19 respiratory failure in the TESICO trial?

The TESICO authors report that aviptadil did not significantly improve clinical outcomes up to day 90 compared with placebo, with an odds ratio of 1.11 (95% CI 0.80–1.55; p=0.54).3 Day 90 mortality was 38% with aviptadil and 36% with placebo.3

Why was the TESICO aviptadil trial stopped?

The independent data and safety monitoring board recommended stopping it on May 25, 2022 for futility.3

Has the FDA authorised aviptadil for emergency use in COVID-19?

Trade reports state that the FDA declined an emergency use authorisation request from NRx Pharmaceuticals in November 2021 and, in a report of 1 July 2022, an application for patients who had received remdesivir and continued to progress.8,9

Has VIP been tested in sarcoidosis?

Prasse and colleagues treated 20 patients with active sarcoidosis with nebulised VIP for 4 weeks in an open phase II study.2 They report reduced tumor necrosis factor-alpha production by bronchoalveolar lavage cells.2

What side effects did aviptadil cause in the TESICO trial?

Diarrhea, facial flushing, tachycardia and hypotension occurred more frequently on aviptadil than placebo.3 Infusions were discontinued for an adverse event in 24 (10%) aviptadil and 13 (6%) placebo participants.3

Has intranasal VIP been studied in a published trial?

No trial of intranasal VIP in people was identified among the 20 titles listed by a query of PubMed on 16 November 2026, which returned 26 records.

12

References

  1. Domschke S, et al. Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut 1978;19(11):1049-53. PMID 730072
  2. Prasse A, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 2010;182(4):540-8. PMID 20442436
  3. Brown SM, et al. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respir Med 2023. PMID 37348524
  4. ClinicalTrials.gov. NCT04311697: Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure. Sponsor: APR Applied Pharma Research s.a. NCT04311697
  5. ClinicalTrials.gov. NCT06729606: Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial). Sponsor: NIAID. NCT06729606
  6. ClinicalTrials.gov. NCT04536350: Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS. NCT04536350
  7. Invicorp 25 micrograms/2 mg solution for injection (aviptadil and phentolamine mesilate). Evolan Pharma AB. Swedish summary of product characteristics (produktresumé), revised 2026. Invicorp product information
  8. Ovey A. FDA decline Emergency Use Authorisation for ZYESAMI in patients with critical COVID. Pharmafile, 5 November 2021. Pharmafile report
  9. Managed Healthcare Executive. FDA declines EUA request for Zyesami for COVID-19. 2022. Managed Healthcare Executive report